Drug Profile
HOE 934553
Latest Information Update: 06 Aug 1998
Price :
$50
*
At a glance
- Originator Aventis
- Class Anti-ischaemics
- Mechanism of Action Selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ischaemic heart disorders
Most Recent Events
- 06 Aug 1998 No-Development-Reported for Ischaemic heart disorders in Germany (Unknown route)
- 12 Dec 1996 Preclinical development for Ischaemic heart disorders in Germany (Unknown route)